Know Labs Announces Technology Webcast

Download as PDF

Technology Overview and Q & A hosted by BioPub

SEATTLE--(BUSINESS WIRE)-- Know Labs, Inc. (OTCQB: KNWN) – a creator and provider of diagnostic solutions, announced the publication of a webcast hosted by BioPub, a biotech investment discussion website found at www.biopub.co.

The webcast was moderated by BioPub’s founder and editor in chief, Dr. KSS, MD, Ph.D. Participants from Know Labs were Phil Bosua, CEO, Ron Erickson, Chairman and Dr. James “Andy” Anderson, Chief Medical Officer. The webcast included an overview of the Know Labs technology and a question and answer session.

In addition to discussing the Know Labs technology and its application in a wearable as a non-invasive continuous glucose monitor and other applications, the Company discussed its current financing the details of which can be located on www.flashfunders.com/knowlabs.

About Know Labs, Inc.

Know Labs, Inc. is a public company whose shares trade under the stock symbol “KNWN.” The company’s technology directs structured light or radio waves through a substance or material to capture a unique molecular signature. The Company refers to these signatures as ChromaID™ and Bio-RFID™. ChromaID and Bio-RFID are used to identify, detect, or diagnose substance markers or biomarkers that may be invisible to the human eye. ChromaID and Bio-RFID scanner modules can be integrated into a variety of wearable, mobile or bench-top form factors. This patented and patent pending, award-winning technology makes it possible to effectively conduct analyses that could only previously be performed by invasive and/or large and expensive lab-based tests. For more information on Know Labs, visit the company’s website at www.knowlabs.co.

Safe Harbor Statement

This release contains statements that constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements appear in a number of places in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of Know Labs, Inc., its directors or its officers with respect to, among other things: (i) financing plans; (ii) trends affecting its financial condition or results of operations; (iii) growth strategy and operating strategy. You can identify these statements by the use of the words “may,” “will,” “could,” “should,” “would,” “plans,” “expects,” “anticipates,” “continue,” “estimate,” “project,” “intend,” “likely,” “forecast,” “probable,” “potential,” and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond Know Labs, Inc.’s ability to control, and actual results may differ materially from those projected in the forward-looking statements as a result of various factors. These risks and uncertainties also include such additional risk factors as are discussed in the Company’s filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended September 30, 2018, Forms 10-Q and 8-K, and in other filings we make with the Securities and Exchange Commission from time to time. These documents are available on the SEC Filings section of the Investor Relations section of our website at www.knowlabs.co. The Company cautions readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. The Company undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date on which such statement is made.

Know Labs, Inc. Contact:
Jordyn Theisen
jordyn@knowlabs.co
Ph. 319-321-8470

Source: Know Labs, Inc.

Released September 24, 2019